Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CHANGE

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13,572 result(s) found for: CHANGE. Displaying page 159 of 679.
    «« First « Previous 155  156  157  158  159  160  161  162  163  Next» Last»»
    EudraCT Number: 2017-003372-31 Sponsor Protocol Number: LJ401-BT01 Start Date*: 2018-03-20
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A Multi-center, Randomized, Open-Label, Parallel-Group Study with LJPC-401 for the Treatment of Myocardial Iron Overload in Patients with Transfusion-Dependent Beta Thalassemia
    Medical condition: Transfusion-dependent beta thalassemia with myocardial iron overload
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) CY (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004022-15 Sponsor Protocol Number: ANB019-003 Start Date*: 2020-04-21
    Sponsor Name:AnaptysBio Inc
    Full Title: A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis
    Medical condition: Palmoplantar pustulosis (PPP)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037159 Psoriasis pustular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004255-70 Sponsor Protocol Number: 205687 Start Date*: 2017-05-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasa...
    Medical condition: Treatment of nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-005552-11 Sponsor Protocol Number: LTS12869 Start Date*: 2022-03-07
    Sponsor Name:Genzyme Corporation
    Full Title: A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa.
    Medical condition: Pompe disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10053185 Glycogen storage disease type II PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000107-17 Sponsor Protocol Number: EAT2TREAT Start Date*: 2013-05-22
    Sponsor Name:Hospital of the University of Munich, Grosshadern
    Full Title: Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of 4-aminopyridine sustained-release (Fampyra TM) and acetazolamide (Acemit TM)
    Medical condition: Familial episodic ataxia (EA) represents a genetically and phenotypically diverse group of rare autosomal dominant hereditary disorders characterized by episodes of imbalance and incoordination tha...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10067447 Episodic ataxia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002612-14 Sponsor Protocol Number: TMP-0517 Start Date*: 2019-06-25
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
    Full Title: Preliminary efficacy and safety of Apremilast in the treatment of acne conglobata: A phase II, single centre, open label, proof of concept study for the treatment of acne conglobata with the PDE-4 ...
    Medical condition: Mild to severe Acne conglobata in adults (ages 18 to 65 years, inclusive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000501 Acne conglobata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003951-44 Sponsor Protocol Number: ΕΑΕ-2017/ΜΜ01 Start Date*: 2017-12-15
    Sponsor Name:Hellenic Society of Hematology
    Full Title: A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and /or Refractory Multiple M...
    Medical condition: Relapsed and /or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002177-62 Sponsor Protocol Number: SU-M-01 Start Date*: 2012-11-05
    Sponsor Name:ALK-Abelló A/S
    Full Title: A Dose Response Evaluation of SLIToneULTRA HDM Mix Immunotherapy
    Medical condition: Allergic rhinitis induced by house dust mites (HDM)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002182-36 Sponsor Protocol Number: VRX-RET-E22-302 Start Date*: 2006-04-18
    Sponsor Name:Valeant Research & Development
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP PHASE 3 STUDY TO DETERMINE THE EFFICACY AND SAFETY OF TWO DOSES OF RETIGABINE (900 MG/DAY AND 600 MG/DAY) USED AS ADJUNCT...
    Medical condition: Refractory Epilepsy Patients with Partial-Onset Seizures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) ES (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002448-15 Sponsor Protocol Number: LJ501-CRH01 Start Date*: 2016-03-18
    Sponsor Name:La Jolla Pharmaceutical Company, Inc.
    Full Title: A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients with Catecholamine-Resistant Hypotension (CRH)
    Medical condition: Catecholamine-Resistant Hypotension
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021097 - Hypotension 10049705 Acute hypotension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002539-24 Sponsor Protocol Number: MICA Start Date*: 2012-05-03
    Sponsor Name:Hospital of the University of Munich
    Full Title: Effect of Mipomersen on LDL-Cholesterol Levels in Patients with Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis
    Medical condition: In this trial, the effect of mipomersen is tested on LDL-cholesterol levels in patients with severe LDL-hypercholesterolemia and atherosclerosis which are regularly treated by LDL-apheresis.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10027424 Metabolic and nutritional disorders congenital HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000121-32 Sponsor Protocol Number: 68284528MMY2001 Start Date*: 2019-09-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002728-19 Sponsor Protocol Number: PQ-421a-004 Start Date*: Information not available in EudraCT
    Sponsor Name:ProQR Therapeutics IV B.V.
    Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t...
    Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NO (Prematurely Ended) DK (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002407-10 Sponsor Protocol Number: 17/0238 Start Date*: 2018-03-23
    Sponsor Name:University College London
    Full Title: A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery.
    Medical condition: Obesity.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10068900 Bariatric surgery LLT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002790-38 Sponsor Protocol Number: 1603221 Start Date*: 2016-07-07
    Sponsor Name:Royal Devon & Exeter NHS Foundation Trust
    Full Title: TriMaster: Randomised Double-Blind Crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as third line therapy in patients with type 2 diabetes who have suboptimal glycaemic co...
    Medical condition: Type 2 Diabetes Patients with type 2 diabetes who have suboptimal glycaemic control (HbA1c >58mmol/mol, 58%) on one or two oral therapies, not including a thiazolidinedione, a DPP4 inhibitor or a S...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-000100-37 Sponsor Protocol Number: V01-126A-202 Start Date*: 2022-01-03
    Sponsor Name:Bausch Health Americas, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% adapalene/2.5% BPO), in the Treat...
    Medical condition: Acne Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000554-38 Sponsor Protocol Number: D-FR-52120-221 Start Date*: 2015-07-24
    Sponsor Name:Ipsen Innovation
    Full Title: A Phase III, Multicenter, Double Blind, Randomised, Placebo Controlled Study to Assess the Efficacy and the Safety of a Single Cycle of Dysport Solution in the Treatment of Upper Limb Spasticity in...
    Medical condition: upper limb spastic hemiparesis due to stroke
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10058978 Spastic hemiparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002805-88 Sponsor Protocol Number: J2A-MC-GZGI Start Date*: 2021-09-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities
    Medical condition: Obesity and Overweight with Weight-Related Comorbidities
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-002046-71 Sponsor Protocol Number: CLIK066X2204 Start Date*: 2017-10-20
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-week randomized, patient and investigator blinded, placebo-controlled, parallel group study to investigate the efficacy of LIK066 in obese patients with non-alcoholic steatohepatitis (NASH)
    Medical condition: obese patients with non-alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003441-42 Sponsor Protocol Number: D169EC00001 Start Date*: 2019-05-22
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients wi...
    Medical condition: Heart Failure Patients with Preserved Ejection Fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) SK (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 155  156  157  158  159  160  161  162  163  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 11:44:28 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA